TRINETRA › Sectors › Healthcare
Caplin Point Laboratories Limited (CAPLIPOINT) — share price, P/E and fundamentals
Caplin Point Laboratories Limited (NSE: CAPLIPOINT) closed at ₹2,331.00 on 30 Oct 2026, +17.3% over one year, against a 52-week range of ₹1,500.30 – ₹2,990.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 12 Aug 2026) it reported revenue of ₹610 cr and net profit of ₹177 cr, a 29.0% net margin; revenue grew 19.6% and profit grew 22.1% year on year.
On four consecutive filed quarters its trailing P/E is 26.6; since 15 May 2025 its own P/E has ranged from 18.6 to 33.2 (median 28.4), and today's reading is higher than 31% of those 361 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 19.7%, ROCE 24.6%, debt-to-equity 0.00, Piotroski F-score 4 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 97% of 63 sector peers; PBT margin higher than 95% of 63 sector peers; ROE higher than 75% of 63 sector peers.
Key figures
| Last close | ₹2,331.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -18.7% / +35.6% / +17.3% |
| 52-week low – high | ₹1,500.30 – ₹2,990.00 |
| Market capitalisation | ₹17,716 cr |
| Trailing P/E | 26.6 |
| Price / book | 4.94 |
| EV / EBITDA | 19.1 |
| Earnings yield | 3.8% |
| TTM EPS | ₹87.55 |
| TTM net profit | ₹665 cr |
| Quarter revenue | ₹610 cr |
| Quarter net profit | ₹177 cr |
| Net margin | 29.0% |
| Revenue growth (YoY) | +19.6% |
| Profit growth (YoY) | +22.1% |
| Return on equity | 19.7% |
| ROCE | 24.6% |
| Debt / equity | 0.00 |
| Current ratio | 6.70 |
| Free cash flow | ₹275 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹27.9 cr |
Against Healthcare peers
| Metric | CAPLIPOINT | Peer median | Percentile |
|---|---|---|---|
| Net margin | 28.98 | 12.67 | 97 |
| PBT margin | 36.90 | 17.57 | 95 |
| ROE | 19.73 | 13.86 | 75 |
| ROCE | 24.64 | 16.59 | 78 |
| Debt / equity | 0.00 | 0.11 | 12 |
| Cash conversion | 0.81 | 1.25 | 18 |
| Trailing P/E | 26.63 | 43.26 | 19 |
| P/B | 4.94 | 6.02 | 41 |
Questions
What is the P/E ratio of Caplin Point Laboratories Limited?
Caplin Point Laboratories Limited's trailing P/E is 26.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 15 May 2025 its P/E has ranged 18.6–33.2.
What were Caplin Point Laboratories Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Caplin Point Laboratories Limited reported revenue of ₹610 cr and net profit of ₹177 cr (consolidated), filed with the exchange on 12 Aug 2026.
What is Caplin Point Laboratories Limited's ROE?
Return on equity is 19.7% based on the balance sheet dated 31 Mar 2026.
Does Caplin Point Laboratories Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.
What is CAPLIPOINT's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, CAPLIPOINT traded between ₹1,500.30 and ₹2,990.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.